With the aim to improve the clinical diagnosis of FTD, we can hypothesize to set up a complete panel of biomarkers including proNGF and NGF to other fluids or imaging biomarkers related to neuroinflammation (such as for instance in Malpetti et al., 2023) or to NGF metabolism. Here, NGF is linked to frontotemporal dementia.